The British National Formulary is the unrivalled guidance on prescribing, dispensing and administering medicines.

The BNF is the only drug formulary in the world that is both independent, and has rigorous, accredited content creation processes. It is trusted by health professionals worldwide as their primary source for minimising medication errors.

SubscribeContent Updates
Features and Benefits icon

Speed and safety: Provides rapid reference to essential information on the selection of safe and effective medicines for individual patients

Features and Benefits icon

Evidence Grading: As part of NICE accreditation recommendations, BNF content is now evidence graded to reflect the strength of evidence behind them, increasing transparency to support healthcare professionals with clinical decision making

Features and Benefits icon

Always up-to-date: The content is revalidated, revised, and updated on a monthly basis, making sure you have access to the very latest prescribing knowledge

Features and Benefits icon

Worldwide credibility: The BNF uses clinical evidence from a diverse range of sources and a network of experts, giving you the confidence to select medicines safely

1,500 +

drugs

290,000 +

users per month

200 +

treatment summaries

45million +

page views

Publication Updates

09 Jun
British National Formulary logo
BNF June 2020 Update

This update contains 7 significant changes, 2 dose changes and 8 new preparations.

Significant Changes:

  • Adrenaline/epinephrine auto-injectors (Emerade®): all strengths of auto-injector pens have been recalled from patients due to failure to activate. Healthcare professionals are advised to ensure that patients who have previously been prescribed an Emerade® 150, 300 or 500 microgram pen are supplied with a prescription for an alternative brand—see the MHRA website for full details [MHRA/CHM advice].
  • Hypoglycaemia: updated guidance on management.
  • Lenalidomide with rituximab for previously treated follicular lymphoma [NICE guidance].
  • Nurse Prescribers’ Formulary: list of medicinal preparations updated with indications for use by Community Practitioner Nurse Prescribers and links to BNF monographs. For further information, see How to use the NPF in the Nurse Prescribers’ Formulary (NPF).
  • Poisoning, emergency treatment: updated guidance on the management of beta-blockers poisoning in-line with TOXBASE recommendations.
  • Poisoning, emergency treatment: updated guidance on the management of paracetamol poisoning in-line with TOXBASE recommendations.
  • Skin infections, antibacterial therapy: updated guidance on management of impetigo.

Dose Changes:

  • Co-fluampicil [update to dosing information].
  • Fostair® NEXThaler 100/6 (beclometasone with formoterol) [dosing for maintenance and reliever therapy added].

New Preparations:

  • Ampres® [chloroprocaine hydrochloride].
  • Beovu® [brolucizumab].
  • Combisal® 25/50 [fluticasone with salmeterol].
  • Combisal® 25/125 [fluticasone with salmeterol].
  • Combisal® 25/250 [fluticasone with salmeterol].
  • Fusacomb 50/250 Easyhaler® [fluticasone with salmeterol].
  • Fusacomb 50/500 Easyhaler® [fluticasone with salmeterol].
  • Staladex® [leuprorelin acetate].

For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm 

12 May
British National Formulary logo
BNF May 2020 Update

This update contains 12 significant changes, 3 dose changes and 5 new preparations.

Significant Changes:

• Baricitinib (Olumiant®): risk of venous thromboembolism [MHRA/CHM advice].
• Benzodiazepines: reminder of risk of potentially fatal respiratory depression [MHRA/CHM advice] (advice in alprazolam, chlordiazepoxide hydrochloride, clobazam, clonazepam, diazepam, flurazepam, loprazolam, lorazepam, lormetazepam, midazolam, nitrazepam, oxazepam, temazepam; see example in diazepam).
• Canagliflozin (SGLT2 inhibitors): monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness [MHRA/CHM advice].
• COVID-19: new guidance incorporating a collection of resources.
• Dapagliflozin (SGLT2 inhibitors): monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness [MHRA/CHM advice].
• Empagliflozin (SGLT2 inhibitors): monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness [MHRA/CHM advice].
• Ertugliflozin (SGLT2 inhibitors): monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness [MHRA/CHM advice].
• Opioids: reminder of risk of potentially fatal respiratory depression [MHRA/CHM advice] (advice in alfentanil, buprenorphine, codeine phosphate, diamorphine hydrochloride, dihydrocodeine tartrate, dipipanone hydrochloride, fentanyl, hydromorphone hydrochloride, meptazinol, methadone hydrochloride, morphine, oxycodone hydrochloride, pentazocine, pethidine hydrochloride, remifentanil, sufentanil, tapentadol, tramadol hydrochloride; see example in morphine).
• Skin infections, antibacterial therapy: new guidance for management of leg ulcer infection.
• Tofacitinib (Xeljanz®): new measures to minimise risk of venous thromboembolism and of serious and fatal infections [MHRA/CHM advice].
• Ulipristal acetate (Esmya®): suspension of the licence due to risk of serious liver injury [MHRA/CHM advice].
• Upadacitinib (Rinvoq®▼): advice for venous thromboembolism [MHRA/CHM advice].

Dose Changes:
• Betamethasone with clioquinol [updated child age range].
• Glucagon [update to age ranges for hypoglycaemia].
• Sodium fluoride [updating dosing for prophylaxis of dental caries].
New Preparations: Cytotect® [cytomegalovirus immunoglobulin], Evenity® [romosozumab], Polivy® [polatuzumab vedotin], Poteligeo® [mogamulizumab], Ultomiris® [ravulizumab].

For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm

14 Apr
British National Formulary logo
BNF April 2020 Update

This update contains 13 significant changes, 5 dose changes and 2 new preparations.

Significant Changes:
• Adrenaline/epinephrine (Emerade®) pre-filled auto-injector: update on failure to activate [MHRA/CHM advice].
• Alemtuzumab (Lemtrada®): updated restrictions and strengthened monitoring requirements following review of serious cardiovascular and immune-mediated reactions [MHRA/CHM advice].
• Antimicrobial stewardship: new guidance.
• Cardiovascular disease risk assessment and prevention: updated guidance.
• Dapagliflozin with insulin for treating type 1 diabetes [NICE guidance].
• Diverticular disease and diverticulitis: updated guidance on management.
• Etonogestrel (Nexplanon®) contraceptive implants: new insertion site to reduce rare risk of neurovascular injury and implant migration [MHRA/CHM advice].
• Gastro-intestinal system infections, antibacterial therapy: updated guidance for acute diverticulitis.
• Ingenol mebutate gel (Picato®): suspension of the licence due to risk of skin malignancy [MHRA/CHM advice].
• Medicines optimisation: new guidance.
• Modafinil: potential risk of congenital malformations during pregnancy [MHRA/CHM advice].
• Patiromer calcium for treating hyperkalaemia [NICE guidance].
• Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis [NICE guidance].

Dose Changes:
• Benzoin tincture, compound [updated child age range].
• Ergotamine tartrate with caffeine hydrate and cyclizine hydrochloride [addition of max. courses per month].
• Eucalyptus with menthol [frequency of dosing].
• Fluocinolone acetonide with clioquinol [updated dosing frequency].
• Paracetamol with buclizine hydrochloride and codeine phosphate [child age ranges].

New Preparations:
Benzathine benzylpenicillin, Mayzent® [ siponimod ].

For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm

10 Mar
British National Formulary logo
BNF March 2020 Update

This update contains 13 significant changes and 3 new preparations.

Significant Changes: 

• Cannabidiol with clobazam for treating seizures associated with Dravet syndrome [NICE guidance].

• Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome [NICE guidance].

• Diabetic foot infections, antibacterial therapy: new guidance on management.

• Malaria, prophylaxis: updated country recommendations in the recommended regimens for prophylaxis against malaria in-line with Public Health England.

• Malaria, prophylaxis: updated guidance in-line with Public Health England recommendations.

• Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [NICE guidance].

• Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy [MHRA/CHM advice].

• Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer [NICE guidance].

• Pain, Chronic: new guidance on management.

• Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer [NICE guidance].

• Pneumococcal vaccine: updated guidance in-line with Public Health England recommendations.

• Sodium valproate: updated Pregnancy Prevention Programme [MHRA/CHM advice].

• Valproic acid: updated Pregnancy Prevention Programme [MHRA/CHM advice].

New Preparations: Aritso® [strontium ranelate], Rinvoq® [upadacitinib], Zalkya® [dienogest].

For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm

11 Feb
British National Formulary logo
BNF February 2020 Update

This update contains 9 significant changes, 1 dose change and 1 new preparation.

Significant Changes

  • Cladribine for treating relapsing–remitting multiple sclerosis [NICE guidance].
  • Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents [MHRA/CHM advice].
  • Hypertension: updated guidance on management.
  • Immunisation schedule: changes to infant schedule for pneumococcal polysaccharide conjugate vaccine in-line with Public Health England recommendations.
  • Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure [NICE guidance].
  • Multiple sclerosis and Nausea and labyrinth disorders: updated guidance for use of cannabis-based medicinal products.
  • Skin infections, antibacterial therapy: updated guidance for management of cellulitis and erysipelas.
  • Tuberculosis: updated guidance on management.
  • Yellow fever vaccine: updated guidance in-line with Public Health England recommendations.

Dose Changes

  • Syner-KINASE® ( urokinase ) [clarification of the intravenous infusion dosage units for the follow-on treatment of pulmonary embolism].

New Preparations

  • Mulpleo® [ lusutrombopag ].

 

For further details on changes in the BNF click on

http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm

14 Jan
British National Formulary logo
BNF January 2020 Update

This update contains 12 significant changes and 5 new preparations. 

Significant Changes:  

  • Ambrisentan (Volibris®): patient alert card available [MHRA/CHM advice]. 
  • Asthma, acute: updated guidance on management. 
  • Asthma, chronic: updated guidance on management. 
  • Carfilzomib (Kyprolis®): risk of reactivation of hepatitis B virus [MHRA/CHM advice]. 
  • Chronic obstructive pulmonary disease: updated guidance on management. 
  • Dyspepsia, Gastro-oesophageal reflux disease, and Peptic ulcer disease: updated guidance and dosing regimens. 
  • Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy [NICE guidance]. 
  • Helicobacter pylori infection: updated guidance and dosing regimens. 
  • Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab [NICE guidance]. 
  • Pentosan polysulfate sodium for treating bladder pain syndrome [NICE guidance]. 
  • Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [NICE guidance]. 
  • Yellow fever vaccine, live: stronger precautions in people with weakened immunity and in those aged 60 years or older [MHRA/CHM advice]. 

New PreparationsNerlynx® [neratinib], Pepto-Bismol® [bismuth subsalicylate], Softacort® [hydrocortisone eye drops], Vaborem® [meropenem with vaborbactam], Xospata® [gilteritinib]. 
 
For further details on changes in the BNF click on http://www.medicinescomplete.com/mc/bnf/current/PHP107699-changes.htm 

View more View all content updates